FDA grants orphan-drug designation to BERG’s candidate BPM31510
Boston-based Biopharmaceutical company, BERG proclaimed that the U.SS FDA has extended orphan-drug designation to the Company's leading product candidate BPM31510, for the treatment of…
Read More...
Read More...